Candel Therapeutics Inc. (CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies to help patients fight cancer, is expected to share updates on its clinical programs - CAN-2409 and CAN-3110 - this year.
CAN-2409 is an off-the-shelf adenovirus product candidate, which is administered in conjunction with the prodrug valacyclovir, that has generated promising clinical activity across a range of solid tumor indications. It is being explored in the indications of prostate cancer, non-small cell lung cancer and pancreatic cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com